SINT
Sintx Technologies, Inc.
$2.03
-9.38%
$9.7M
No data for this timeframe.
Vol
Market Cap$9.7M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders3 funds
Inst. Value$171.7K
Inst. Activity2 buys / 2 sells
Insider Activity3B / 0S
Insider Net $$27.0K
SEC Reports3
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001269026·Prev Close $2.24
Recent Activity
Jun 3, 2026
SEC
SINTX Technologies entered into a securities purchase agreement to raise between $5M and $7M through the sale of units c
8-K — Impact 7/10
May 27, 2026
SEC
SINTX Technologies received a Nasdaq delisting notice on May 22, 2026, for failing to meet the minimum $2.5 million stoc
8-K — Impact 7/10
May 11, 2026
earnings_calendar
SINT Q1 2026 Earnings Scheduled — 2026-05-11
Apr 13, 2026
Insider
Elmore Robert Ryan sold 4,910 shares
President @ $2.89 ($14.2K)
Mar 23, 2026
Press
SINTX Technologies announced a clinical milestone with the first human implant of its FDA-cleared SINAPTIC Foot & Ankle
Impact 4/10
Mar 16, 2026
Insider
Elmore Robert Ryan sold 107,143 shares
President @ $0.00 ($0.00)
Mar 10, 2026
SEC
Analysis based on filing metadata only — document content was unavailable. This is an insider trading cluster filing for
CLUSTER — Impact 3/10
Mar 2, 2026
Insider
Lyons Christopher Michael bought 7,534 shares
Director @ $2.90 ($21.8K)
Price Targets
$10.17
+400.8% upside
Strong Buy
Current $2.03
Low $8.50
Median $10.00
High $12.00
3 analysts
$8.50
$12.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 13, 2026 | HC Wainwright & Co. | INITIATE | Buy |
| Apr 8, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Dec 8, 2025 | Ascendiant Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.81 ▼ -20.9% | $-0.81 — $-0.81 | 23% YoY | 1 |
| Next Q | $-0.43 ▲ +9.5% | $-0.43 — $-0.43 | 88% YoY | 1 |
| Current FY | $-2.27 ▼ -5.3% | $-2.27 — $-2.27 | 63% YoY | 1 |
| Next FY | $-1.70 ▲ +3.1% | $-1.90 — $-1.50 | 25% YoY | 2 |
Latest Reports
BEARISH
8-K
7/10
SINTX Technologies entered into a securities purchase agreement to raise between $5M and $7M through the sale of units c
Jun 3, 2026
BEARISH
8-K
7/10
SINTX Technologies received a Nasdaq delisting notice on May 22, 2026, for failing to meet the minimum $2.5 million stoc
May 27, 2026
NEUTRAL
Press
4/10
SINTX Technologies announced a clinical milestone with the first human implant of its FDA-cleared SINAPTIC Foot & Ankle
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $171.5K | ADD |
| BANK OF AMERICA CORP | $120.00 | ADD |
| MORGAN STANLEY | $70.00 | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 13, 2026 | Elmore Robert | A | $14.2K |
| Mar 16, 2026 | Elmore Robert | A | $0.00 |
| Mar 2, 2026 | Lyons Christopher | BUY | $21.8K |
| Feb 25, 2026 | Lyons Christopher | BUY | $2.2K |
| Feb 23, 2026 | MOYES JAY | BUY | $2.9K |
3 institutional holders with $171.7K total value (44,485 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 44,436 | $171.5K | 99.9% | ADD +46.0% |
| 2 | BANK OF AMERICA CORP /DE/ | 31 | $120.00 | 0.1% | ADD +47.6% |
| 3 | MORGAN STANLEY | 18 | $70.00 | 0.0% | TRIM -37.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 30,430 | 44,436 | +46.0% | $171.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 21 | 31 | +47.6% | $120.00 | 2025-Q4 |
| MORGAN STANLEY | TRIM | 29 | 18 | -37.9% | $70.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 27,552 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 27,552 | — | $112.7K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 12 | 29 | +141.7% | $119.00 | 2025-Q3 |
| UBS Group AG | EXIT | 6,421 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | NEW | — | 6,421 | — | $20.7K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 11 | 24 | +118.2% | $77.00 | 2025-Q2 |
| VANGUARD GROUP INC | NEW | — | 30,430 | — | $80.9K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 21,900 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 21,900 | — | $76.7K | 2024-Q4 |
| UBS Group AG | DOUBLED | 341 | 1,584 | +364.5% | $5.5K | 2024-Q4 |
6 unique insiders with 3 transactions. Net insider value: $27.0K ($27.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 13, 2026 | Elmore Robert Ryan | President | A | 4,910 | $2.89 | $14.2K |
| Mar 16, 2026 | Elmore Robert Ryan | President | A | 107,143 | $0.00 | $0.00 |
| Mar 2, 2026 | Lyons Christopher Michael | Director | BUY | 7,534 | $2.90 | $21.8K |
| Feb 25, 2026 | Lyons Christopher Michael | Director | BUY | 758 | $2.96 | $2.2K |
| Feb 23, 2026 | MOYES JAY M | Director | BUY | 1,000 | $2.91 | $2.9K |
| Feb 6, 2026 | Honigblum Gregg R. | Chief Investment Officer | A | 75,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Olson Eric K. | Chairman, President and CEO | A | 100,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Trask Kevin | Chief Financial Officer | A | 60,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
BEARISH
8-K
7/10
SINTX Technologies entered into a securities purchase agreement to raise between $5M and $7M through
Jun 3, 2026
BEARISH
8-K
7/10
SINTX Technologies received a Nasdaq delisting notice on May 22, 2026, for failing to meet the minim
May 27, 2026
NEUTRAL
CLUSTER
3/10
Analysis based on filing metadata only — document content was unavailable. This is an insider tradin
Mar 10, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.17 mean target
+400.8% upside
Strong Buy (1.00)
$8.50 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $2.03 |
| Target Low | $8.50 |
| Target Mean | $10.17 |
| Target Median | $10.00 |
| Target High | $12.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.81 | $-0.81 | $-0.81 | 23.1% | -20.9% | 0↑ 1↓ | $0.0B | 231.1% | 1 |
| Next Q 2026-09-30 |
$-0.43 | $-0.43 | $-0.43 | 87.6% | +9.5% | 0↑ 1↓ | $0.0B | 140.4% | 1 |
| Current FY 2026-12-31 |
$-2.27 | $-2.27 | $-2.27 | 63.1% | -5.3% | 0↑ 1↓ | $0.0B | 86.6% | 1 |
| Next FY 2027-12-31 |
$-1.70 | $-1.90 | $-1.50 | 25.1% | +3.1% | 1↑ 0↓ | $0.0B | 168.4% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.810 | |
| 7d ago | $-0.670 | -0.140 |
| 30d ago | $-0.670 | -0.140 |
| 60d ago | $-0.550 | -0.260 |
| 90d ago | $-0.550 | -0.260 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Apr 8, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Dec 8, 2025 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
earnings_calendar
SINT Q1 2026 Earnings Scheduled — 2026-05-11
Mar 23, 2026
leadership
SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution
<p align="center"><i>Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in
Mar 19, 2026
other
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
<p align="center"><i>Major clinical milestone marks SINTX’s entry into the foot and ankle reconstruction market and advances commercialization of its
Mar 17, 2026
earnings_calendar
SINT Q4 2026 Earnings Scheduled — 2026-03-17